Affiliate disclosure: some links on this page are affiliate links and may earn us a commission at no extra cost to you — it never affects our rankings or reviews.

Guide · Medicare · United States

Does Medicare cover Zepbound?

Yes, in some cases: from July 1, 2026 Medicare's GLP-1 Bridge covers the Zepbound KwikPen for $50 a month if you meet the criteria; Zepbound vials are not included. The Bridge runs to December 31, 2027 and needs prior authorization from your prescriber, and people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease use their Part D plan instead.

Every fact on this page carries its source and date; we read them on October 30, 2026. This is general information, not advice about your plan or your health: a clinician decides whether a medicine is right for you, and Medicare or your plan decides coverage.

Edited by Gabriel BrocklesbyFounder & EditorFact-checkedLast updated

Who is eligible for the Medicare GLP-1 Bridge

The Medicare GLP-1 Bridge is a short-term CMS demonstration running from July 1, 2026 to December 31, 2027. It covers Foundayo (tablet), Wegovy (injection or tablet), Zepbound KwikPen. To use the Bridge you must be 18 or older and, at the start of treatment, have one of the following. The medicine must be prescribed for weight reduction and maintenance, alongside changes to diet and activity.

  • A BMI of 35 or higher.
  • A BMI of 30 or higher with heart failure with preserved ejection fraction (HFpEF), uncontrolled high blood pressure (systolic above 140 or diastolic above 90 despite two blood pressure medicines) or chronic kidney disease stage 3a or later.
  • A BMI of 27 or higher with prediabetes, a previous heart attack, a previous stroke or symptomatic peripheral artery disease.

The Bridge is not for people with type 2 diabetes, people with moderate-to-severe obstructive sleep apnea, people with fatty liver disease (MASH): they use their Part D plan, which may already cover a GLP-1 for those conditions. Nor is it for people already getting a GLP-1 (semaglutide, tirzepatide, orforglipron, dulaglutide or liraglutide) through Part D, or people using a GLP-1 for cardiovascular risk reduction, which the CMS sponsor FAQ lists as a Part D-coverable use.

You can use it with a standalone Part D plan (PDP), a Medicare Advantage plan with drug coverage (HMO, HMO-POS, local or regional PPO), a Special Needs Plan, an employer group waiver plan (EGWP) or LI NET. It is not available if your only coverage is PFFS, a section 1876 cost plan, a section 1833 prepayment plan, PACE, a fallback plan or a religious fraternal plan, unless you also have a standalone Part D plan.

Sources: CMS: Medicare GLP-1 Bridge (page last modified July 13, 2026); CMS prescriber fact sheet (No. 12235) (June 2026); Medicare.gov fact sheet: Medicare GLP-1 Bridge (CMS Product No. 12234) (June 2026); CMS: Medicare GLP-1 Bridge expectations and FAQs for Part D sponsors (June 10, 2026); Medicare.gov: Weight loss drugs (no page date). Read October 30, 2026.

How to get it: prior authorization

Your prescriber starts the process; you cannot apply on your own. In outline:

  1. Your prescriber sends the prescription with a weight-management diagnosis code and the note "SEND TO BRIDGE FOR WEIGHT MANAGEMENT".
  2. The Bridge's central processor declines the first claim and asks for prior authorization. Your prescriber submits it electronically or by fax on the CMS form and attests that you meet the criteria.
  3. A decision comes within 72 hours. There is no formal appeal, but your prescriber can resubmit.
  4. An approval lasts to December 31, 2027 unless you switch to a different GLP-1. Refills and dose changes need no new prior authorization; switching medicine does.

Sources: CMS prescriber fact sheet (No. 12235) (June 2026); CMS: Medicare GLP-1 Bridge prior authorization form (no page date); Medicare.gov: Weight loss drugs (no page date); Obesity Medicine Association: updates to Medicare coverage of GLP-1 medications (secondary) (updated July 14, 2026). Read October 30, 2026.

What it costs under the Bridge

  • You pay $50 a month for a covered medicine.
  • The Part D deductible does not apply, and the copay does not count toward your Part D out-of-pocket costs or the out-of-pocket cap.
  • Extra Help (the low-income subsidy) does not apply to Bridge drugs, and the Medicare Prescription Payment Plan cannot be used for them.
  • Manufacturer coupons and discount programs cannot be applied to Bridge claims.
  • Only 28 or 30 day fills are covered, not 60 or 90 day fills.
  • Under the Bridge, the manufacturers supply the medicines at a net price of $245 a month; your share is the $50 copay.

People with both Medicare and Medicaid can use the Bridge if they have qualifying Part D coverage, and still pay the full $50, because Extra Help does not apply. Whether a state Medicaid program pays that copay varies by state: Pennsylvania's will not (PHLP, June 26, 2026).

Sources: CMS: Medicare GLP-1 Bridge (page last modified July 13, 2026); CMS: Medicare GLP-1 Bridge expectations and FAQs for Part D sponsors (June 10, 2026); Medicare.gov fact sheet: Medicare GLP-1 Bridge (CMS Product No. 12234) (June 2026); Healthcare Finance News: Medicare launches the GLP-1 Bridge for eligible Part D beneficiaries (no page date); PHLP: New Medicare program to offer limited coverage for GLP-1 weight loss medications (June 26, 2026). Read October 30, 2026.

Which Zepbound is covered: the KwikPen, not vials

The Bridge covers the Zepbound KwikPen only. Zepbound vials are not included, and neither are Zepbound single-dose pens. If your prescription is for vials, ask your prescriber about the KwikPen before the prior authorization is sent.

Medicare.gov's fact sheet lists the Bridge drugs by product, not by dose.

Sources: Medicare.gov fact sheet: Medicare GLP-1 Bridge (CMS Product No. 12234) (June 2026); CMS prescriber fact sheet (No. 12235) (June 2026). Read October 30, 2026.

Zepbound for sleep apnea: Part D, not the Bridge

Zepbound is also approved for moderate-to-severe obstructive sleep apnea in people with obesity. CMS said in January 2025 that Part D plans can cover Zepbound for that use, and prior authorization may apply. Whether your plan does depends on its formulary.

People with moderate-to-severe sleep apnea are excluded from the Bridge, so for them Part D is the route, not the Bridge.

Sources: NBC San Diego / CNBC: Medicare can now cover Zepbound for sleep apnea, CMS says (January 8, 2025); Medicare.gov fact sheet: Medicare GLP-1 Bridge (CMS Product No. 12234) (June 2026). Read October 30, 2026.

Why Part D does not cover Zepbound for weight loss

Part D law excludes drugs "when used for anorexia, weight loss, or weight gain". A GLP-1 becomes a Part D drug only for an FDA-approved use that is not weight loss, such as Zepbound for sleep apnea. The Bridge works around the exclusion as a CMS demonstration that sits outside the Part D benefit.

Sources: Congressional Research Service In Focus IF12758 (September 9, 2024); CMS: Medicare GLP-1 Bridge (page last modified July 13, 2026). Read October 30, 2026.

If you are not eligible, or not covered

If you have type 2 diabetes, sleep apnea, fatty liver disease or heart disease, ask your Part D plan what it covers for that condition. The Bridge ends on December 31, 2027. CMS has not said what follows: its page says only that Bridge data may inform a possible BALANCE model in Part D, and KFF (April 23, 2026) says CMS's approach after the Bridge is unknown.

The manufacturer sells Zepbound direct for cash, with a prescription you already hold. We list these prices for information; PCF has no commercial relationship with the manufacturer.

  • LillyDirect lists the Zepbound KwikPen at $299 a month at the starting dose, checked November 19, 2026. No membership printed, pen needles sold separately, prescription required. LillyDirect's page
  • LillyDirect lists the Zepbound vial at $299 a month at the starting dose, checked November 19, 2026. No membership printed, needles and syringes sold separately, prescription required. LillyDirect's page

Prices are read daily from each seller's own page; see the brand-name GLP-1 price chart for every seller.

Sources: CMS: Medicare GLP-1 Bridge (page last modified July 13, 2026); KFF: CMS extends Medicare's short-term Bridge program for GLP-1 obesity drug coverage (April 23, 2026). Read October 30, 2026.

Frequently asked questions

Does Medicare cover Zepbound for weight loss?

Yes, in some cases. From July 1, 2026 to December 31, 2027, the Medicare GLP-1 Bridge covers the Zepbound KwikPen for $50 a month for people with Part D coverage who meet the BMI and health criteria, with prior authorization (CMS; Medicare.gov fact sheet, June 2026). Zepbound vials are not included.

Does the Medicare GLP-1 Bridge cover Zepbound vials?

No. The Medicare.gov fact sheet (June 2026) lists the Zepbound KwikPen only; Zepbound single-dose vials and single-dose pens are not covered.

Who qualifies for Zepbound under the Bridge?

Adults 18 or older with a BMI of 35 or higher; or a BMI of 30 or higher with heart failure with preserved ejection fraction (HFpEF), uncontrolled high blood pressure (systolic above 140 or diastolic above 90 despite two blood pressure medicines) or chronic kidney disease stage 3a or later; or a BMI of 27 or higher with prediabetes, a previous heart attack, a previous stroke or symptomatic peripheral artery disease, prescribed for weight reduction alongside lifestyle changes. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are excluded and use Part D (CMS prescriber fact sheet, June 2026).

How much does Zepbound cost with Medicare?

Under the Bridge, $50 a month. The Part D deductible does not apply, the copay does not count toward your out-of-pocket costs, and Extra Help does not reduce it (CMS, 2026).

Does Medicare cover Zepbound for sleep apnea?

Part D plans can cover Zepbound for moderate-to-severe obstructive sleep apnea with obesity (CMS statement, January 2025), subject to the plan's formulary and prior authorization. It is not a Bridge use.

What happens after the Bridge ends?

The Bridge runs to December 31, 2027. CMS has not said what follows, and KFF (April 23, 2026) says its approach after the Bridge is unknown.